Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology · Myeloid/Lymphoid Neoplasm with JAK2 Rearrangement

Symptoms, Eosinophilia, and Red Flags

At a Glance

In JAK2-rearranged myeloid/lymphoid neoplasm, chest pain, severe shortness of breath, stroke-like symptoms, fainting, uncontrolled bleeding, or high fever need urgent care. Hypereosinophilia can damage the heart and lungs, and ruxolitinib should not be stopped suddenly.

Because a myeloid/lymphoid neoplasm (MLN) with JAK2 rearrangement can behave differently over time, your symptoms can change significantly depending on the “phase” of the disease [1]. Understanding these changes and the specific risks of your treatment is critical for your safety.

Symptoms in the Chronic vs. Acute Phases

In the chronic phase (often called the MPN phase), the disease moves slowly. You might feel “constitutional symptoms” like fatigue, night sweats, or unexplained weight loss [2]. Your bone marrow may also produce too many cells, leading to:

  • Enlarged Spleen (Splenomegaly): You may feel a “fullness” or discomfort on the left side of your abdomen [3].
  • Anemia: Low red blood cells can cause weakness and pale skin [1].
  • High White Cell Counts: Elevated white blood cells can cause inflammation [4].

If the disease moves into an acute phase (or blast phase), symptoms typically become more intense and appear more quickly. This may involve a sudden drop in healthy blood cells, leading to easy bruising, frequent infections, or severe shortness of breath [2][5].

The Danger of Hypereosinophilia

Many people with this diagnosis have hypereosinophilia—clinically defined as an absolute eosinophil count of at least 1,500/µL [2]. While eosinophils normally help fight parasites, in this cancer, they can be overproduced. They can infiltrate your organs and release substances that cause inflammation and scarring [6][7].

Organ risk depends on the level, duration, and clinical context. The two most dangerous areas for this damage are:

  1. The Heart (Loeffler Endocarditis): Eosinophils can cause the inner lining of the heart to become inflamed and scarred (fibrosis). This makes the heart stiff and can lead to the formation of blood clots (thrombi) inside the heart chambers [8][6].
  2. The Lungs: Infiltration can cause eosinophilic pneumonia or scarring, making it difficult for your lungs to transfer oxygen to your blood [9][10].

Red Flags: When to Seek Emergency Care

If you experience any of the following, seek immediate medical attention. Do not wait for your hematology team and do not drive yourself. Call 911 immediately:

  • Chest Pain: Any pressure, squeezing, or sharp pain in the chest [11].
  • Sudden or Severe Shortness of Breath (Dyspnea): Feeling like you cannot catch your breath [10][11].
  • Stroke Signs: Sudden weakness (especially on one side), facial drooping, slurred speech, or vision changes [12][13].
  • Fainting or Severe Palpitations: A feeling that your heart is racing [11].

Hematology Emergencies (Call your clinic or go to the ER):

  • Fever of 100.4°F (38°C) or Higher: Especially if you are on treatment.
  • Uncontrolled bleeding or black, tarry stools.
  • Severe headache or sudden confusion.

Medication Safety: The Ruxolitinib Warning

If you are prescribed ruxolitinib (a JAK inhibitor), you must never stop taking it abruptly without your doctor’s supervision [14]. Stopping this medication suddenly can cause a severe disease rebound or a rare but serious discontinuation syndrome (cytokine rebound) [15].

Signs of this syndrome include:

  • Rapidly worsening shortness of breath or respiratory failure [15].
  • Shock or a dangerous drop in blood pressure [14].
  • High fever and a “flu-like” feeling that escalates quickly [15].

If you miss a dose, do NOT double your next dose unless instructed. If you cannot take your dose (for example, due to surgery or an inability to get a refill), contact your hematologist immediately. They will provide an individualized tapering schedule or alternative plan to prevent a rebound [16][17].

Common questions in this guide

What symptoms can JAK2-rearranged myeloid/lymphoid neoplasm cause?
In a slower chronic phase, symptoms may include fatigue, night sweats, unexplained weight loss, left-sided abdominal fullness from an enlarged spleen, weakness, and pale skin. A faster acute or blast phase can cause easy bruising, frequent infections, and severe shortness of breath as healthy blood cells fall.
What eosinophil count is considered hypereosinophilia, and why is it dangerous?
Hypereosinophilia means an absolute eosinophil count of at least 1,500 cells per microliter. Excess eosinophils can enter organs and cause inflammation, scarring, and blood clots, especially in the heart and lungs.
Which symptoms mean I should call 911?
Call 911 immediately for chest pain, sudden or severe shortness of breath, stroke-like signs such as one-sided weakness or slurred speech, fainting, or severe palpitations. Do not drive yourself or wait for your hematology team.
What fever or bleeding symptoms require urgent medical attention?
A temperature of 100.4°F (38°C) or higher, especially while receiving treatment, should prompt a call to your clinic or an emergency evaluation. Uncontrolled bleeding, black or tarry stools, severe headache, or sudden confusion also require urgent medical attention.
Can I stop ruxolitinib suddenly if I feel better or cannot take it?
No. Abruptly stopping ruxolitinib can cause a serious rebound reaction, including worsening breathing problems, dangerously low blood pressure, or high fever. Contact your hematologist so they can arrange a supervised taper or another plan.
What should I do if I miss a ruxolitinib dose?
Do not double the next dose unless your clinician specifically tells you to do so. If you cannot take the medicine, are having surgery, or may run out of refills, contact your hematologist promptly for individualized instructions.

Get notified when new evidence is published on Myeloid/lymphoid neoplasm associated with JAK2 rearrangement.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

    Tang G, Sydney Sir Philip JK, Weinberg O, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(4)):490-498 doi:10.1038/s41379-018-0165-9.

    PMID: 30401948
  2. 2

    How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.

    Reiter A, Metzgeroth G, Cross NCP

    Blood 2025; (145(16)):1758-1768 doi:10.1182/blood.2023022417.

    PMID: 39046810
  3. 3

    A Case of Myeloproliferative Neoplasm with Eosinophilia Associated with PCM1-JAK2 Rearrangement.

    Zhou W, Guo X, Liu Y, et al.

    Case reports in oncology 2025; (18(1)):190-197 doi:10.1159/000542692.

    PMID: 39980500
  4. 4

    Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.

    Zhang L, Shah B, Zhang Y, et al.

    Human pathology 2023; (136()):1-15 doi:10.1016/j.humpath.2023.03.002.

    PMID: 36958463
  5. 5

    T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.

    Schoelinck J, Gervasoni J, Guillermin Y, et al.

    Virchows Archiv : an international journal of pathology 2024; (484(5)):853-857 doi:10.1007/s00428-023-03693-5.

    PMID: 37985498
  6. 6

    Eosinophilic myocarditis: comprehensive update on pathophysiology, diagnosis, prognosis and management.

    Collini V, Burelli M, Favaretto V, et al.

    Minerva cardiology and angiology 2023; (71(5)):535-552 doi:10.23736/S2724-5683.23.06287-7.

    PMID: 37161920
  7. 7

    Loeffler Endocarditis: Multimodality Imaging of a Common Cardiac Phenotype in Distinct Hypereosinophilic Syndromes.

    Salar T, Feitell S, Parikh V, Baibhav B

    JACC. Case reports 2026; (31(31)):108674 doi:10.1016/j.jaccas.2026.108674.

    PMID: 42301176
  8. 8

    Hypereosinophilic syndrome: cardiac diagnosis and management.

    Mankad R, Bonnichsen C, Mankad S

    Heart (British Cardiac Society) 2016; (102(2)):100-6 doi:10.1136/heartjnl-2015-307959.

    PMID: 26567231
  9. 9

    Hypereosinophilic syndrome associated with multiple thromboses requiring ICU admission: A case report.

    Ouanes I, Toumi S, Ben Cheikh Y, et al.

    La Tunisie medicale 2023; (101(10)):783-786.

    PMID: 38465762
  10. 10

    Idiopathic Hypereosinophilic Syndrome in an Elderly Female: A Case Report.

    Khalid F, Holguin F

    The American journal of case reports 2019; (20()):381-384 doi:10.12659/AJCR.912747.

    PMID: 30902963
  11. 11

    Eosinophilic myocarditis in platelet-derived growth factor receptor α-rearranged myeloid neoplasm with central nervous system involvement: a case report.

    Aloini MC, Segreti A, Melfi R, Grigioni F

    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2026; doi:10.4081/monaldi.2026.4166.

    PMID: 42948984
  12. 12

    Hypereosinophilic syndrome with Löffler endocarditis and multiple cerebral infarctions in a patient with a CLL-phenotype clonal B-cell population: a case report.

    Wang H, Zhu F, Hu H

    Frontiers in cardiovascular medicine 2026; (13()):1924869 doi:10.3389/fcvm.2026.1924869.

    PMID: 42688267
  13. 13

    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (FIP1L1::PDGFRA) complicated by Loeffler's endocarditis leading to stroke.

    Luo R, Qi X

    BMC neurology 2026; (26(1)).

    PMID: 42135668
  14. 14

    Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review.

    Houthuys JF, Wilmer AP, Peetermans M, et al.

    Heliyon 2022; (8(12)):e11782 doi:10.1016/j.heliyon.2022.e11782.

    PMID: 36478803
  15. 15

    Rapid Hepatomegaly From Ruxolitinib Discontinuation Syndrome.

    van Rensburg RJ, Hale S, Calara A, et al.

    HCA healthcare journal of medicine 2023; (4(2)):199-204 doi:10.36518/2689-0216.1518.

    PMID: 37424984
  16. 16

    Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.

    Devos T, Selleslag D, Granacher N, et al.

    Hematology (Amsterdam, Netherlands) 2022; (27(1)):23-31 doi:10.1080/16078454.2021.2009645.

    PMID: 34957926
  17. 17

    Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study.

    Mascarenhas J, Nguyen H, Saunders A, et al.

    Future oncology (London, England) 2023; (19(11)):763-773 doi:10.2217/fon-2022-1298.

    PMID: 37161798

This page is for informational purposes only and does not constitute medical advice. It explains symptoms, hypereosinophilia risks, emergency warning signs, and ruxolitinib safety; contact your hematology team for personalized instructions and call 911 for emergencies.